US20050158384A1 - Sustained release delivery of amphetamine salts - Google Patents
Sustained release delivery of amphetamine salts Download PDFInfo
- Publication number
- US20050158384A1 US20050158384A1 US11/030,174 US3017405A US2005158384A1 US 20050158384 A1 US20050158384 A1 US 20050158384A1 US 3017405 A US3017405 A US 3017405A US 2005158384 A1 US2005158384 A1 US 2005158384A1
- Authority
- US
- United States
- Prior art keywords
- amphetamine
- pharmaceutical composition
- sustained release
- salt
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title claims abstract description 74
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 50
- 238000013268 sustained release Methods 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 32
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 31
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 230000036470 plasma concentration Effects 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 21
- 238000000576 coating method Methods 0.000 claims description 42
- 239000011248 coating agent Substances 0.000 claims description 36
- 229920000642 polymer Polymers 0.000 claims description 25
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 24
- 229940025084 amphetamine Drugs 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 11
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 claims description 8
- VHKVKWTWHZUFIA-DGOKBZBKSA-N (2s)-1-phenylpropan-2-amine;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound C[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O VHKVKWTWHZUFIA-DGOKBZBKSA-N 0.000 claims description 6
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 claims description 6
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 229960000632 dexamfetamine Drugs 0.000 claims description 6
- 229940052370 dextroamphetamine saccharate Drugs 0.000 claims description 6
- 229940119751 dextroamphetamine sulfate Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 229940008238 amphetamine sulfate Drugs 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 229950005223 levamfetamine Drugs 0.000 claims description 5
- DAWXRFCLWKUCNS-MNTSKLTCSA-N (2s)-2-aminobutanedioic acid;1-phenylpropan-2-amine;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 DAWXRFCLWKUCNS-MNTSKLTCSA-N 0.000 claims description 4
- 229940030922 amphetamine aspartate monohydrate Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229940047812 adderall Drugs 0.000 abstract description 29
- 230000000541 pulsatile effect Effects 0.000 abstract description 4
- 239000011324 bead Substances 0.000 description 43
- 239000003814 drug Substances 0.000 description 38
- 229940079593 drug Drugs 0.000 description 36
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 31
- 239000003826 tablet Substances 0.000 description 19
- 239000001856 Ethyl cellulose Substances 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229920001249 ethyl cellulose Polymers 0.000 description 18
- 235000019325 ethyl cellulose Nutrition 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000007921 spray Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- -1 Kollicoat SR30D Polymers 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000008188 pellet Substances 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 229920003134 Eudragit® polymer Polymers 0.000 description 8
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000010410 layer Substances 0.000 description 7
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 6
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 4
- MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 4
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 4
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000008116 calcium stearate Substances 0.000 description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
- 235000013539 calcium stearate Nutrition 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 229960004170 clozapine Drugs 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229960001344 methylphenidate Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000024196 oppositional defiant disease Diseases 0.000 description 4
- 229960002296 paroxetine Drugs 0.000 description 4
- 229940035613 prozac Drugs 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 4
- 229940020965 zoloft Drugs 0.000 description 4
- 229940039925 zyprexa Drugs 0.000 description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 3
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940098766 effexor Drugs 0.000 description 3
- 229940011681 elavil Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940049654 glyceryl behenate Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960002048 guanfacine Drugs 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000008185 minitablet Substances 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- 229940055692 pamelor Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940127250 psychostimulant medication Drugs 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 208000001573 Cataplexy Diseases 0.000 description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- OJNSNSZTGUACNI-IBFUIWIBSA-N N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 Chemical compound N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 OJNSNSZTGUACNI-IBFUIWIBSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 208000005439 Sleep paralysis Diseases 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940052327 amphetamine aspartate Drugs 0.000 description 2
- 229940025141 anafranil Drugs 0.000 description 2
- 229940039856 aricept Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940112502 concerta Drugs 0.000 description 2
- 229940099242 dexedrine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940089063 epitol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940108366 exelon Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229940009622 luvox Drugs 0.000 description 2
- JUMYIBMBTDDLNG-UHFFFAOYSA-N methylphenidate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C(=O)OC)C1CCCC[NH2+]1 JUMYIBMBTDDLNG-UHFFFAOYSA-N 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 229940087524 nardil Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940087824 parnate Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229940106887 risperdal Drugs 0.000 description 2
- 229940099204 ritalin Drugs 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229940035004 seroquel Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 229940090016 tegretol Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940009065 wellbutrin Drugs 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- MHNSPTUQQIYJOT-UHFFFAOYSA-N 3-(6h-benzo[c][1]benzoxepin-11-ylidene)propyl-dimethylazanium;chloride Chemical compound Cl.C1OC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 MHNSPTUQQIYJOT-UHFFFAOYSA-N 0.000 description 1
- WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 description 1
- BUCORZSTKDOEKQ-UHFFFAOYSA-N 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine Chemical compound C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 BUCORZSTKDOEKQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 101710171573 Primary amine oxidase Proteins 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940072359 anaprox Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229940057922 carbatrol Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009500 colour coating Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940075922 depacon Drugs 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940084238 eldepryl Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940027804 halcion Drugs 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940073092 klonopin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940061871 lorcet Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229940000596 parlodel Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229940088507 permax Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940117394 provigil Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical group [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 1
- 229940099190 serzone Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- XYGBKMMCQDZQOZ-UHFFFAOYSA-M sodium;4-hydroxybutanoate Chemical compound [Na+].OCCCC([O-])=O XYGBKMMCQDZQOZ-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940118176 surmontil Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229940000146 vicodin Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 229940051225 xyrem Drugs 0.000 description 1
- 229940083488 zonalon Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- compositions for providing an orally administrable sustained release (SR) form of one or more amphetamines and/or amphetamine salts are also described.
- SR sustained release
- methods for administering the sustained release form of one or more amphetamine salts to a patient in need thereof are carried out for treatment of patients having ADHD (attention deficit hyperactivity disorder), but other disease states can also be treated.
- ADHD attention deficit hyperactivity disorder
- the sustained-release forms of one or more amphetamines and/or amphetamine salts according to the invention are preferably formulated to provide an in vivo plasma concentration profile (i.e., measured by total concentration of the amphetamines and/or amphetamine salts (often with separate tracking of d- and l-isomers) in the patients' blood plasma) which is substantially equivalent to the in vivo plasma concentration profile achieved by pulsatile release formulations of the same amphetamines and/or amphetamine salts when administered to a patient, e.g., those achieved by ADDERALL XR®, Shire US Inc., whose FDA package insert and labeling are entirely incorporated by reference herein.
- this sustained release profile typically exhibits first order or biphasic or sigmoidal characteristics.
- the SR formulations according to the invention exhibit a single dose in vivo plasma concentration profile substantially the same as that shown in FIG. 1 .
- the latter shows the substantially smooth mean (over about 20 patients) plasma concentration curves achieved for both the dextroamphetamine and levoamphetamine salts in ADDERALL XR®.
- the overall mean plasma concentration curve for total amphetamine level is simply the sum of the two curves shown in FIG. 1 ).
- the formulations of this invention achieve substantially the same mean plasma concentration curves, they can be termed fast sustained release formulations, with regard to the initial rising slopes involved.
- substantially the same “profile” herein is meant that two curves have substantially the same AUC (area under the curve) and C max , e.g., these parameters for each curve are ⁇ 20% of each other, or even closer, e.g., ⁇ 10%, ⁇ 5%, ⁇ 2%, etc., which parameters are entirely conventionally defined and determined. See, e.g., Fundamentals of Clinical Pharmacokinetics, J. G. Wagner, Drug Intelligence Publications, Inc., Hamilton, Ill., 1975; Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, FDA, CDER, October 2000. For FIG.
- AUC time zero to infinity
- C max is 28.0 ng/mL for d-amphetamine and 205.1 ng hr/mL and 8.7 ng/mL, respectively, for l-amphetamine.
- plasma curves achieved by this invention can follow even more closely the course of a target curve such as that shown in FIG. 1 , e.g., substantially (e.g, ⁇ 20%) matching initial rising slope, post-peak curve shapes, T max values, (7.1 hr for d-amphetamine and 7.4 hr for l-amphetamine for FIG. 1 ), etc.
- FIG. 1 shows data for 20 mg tablets (i.e., two 10 mg pulsatile doses), the plasma curves (and e.g., AUC and C max ) corresponding to other daily doses such as 10, 30, 40, 50, 60, 70, 80, 90 mg will be essentially linearly proportional to those shown in FIG. 1 , corresponding to the involved dosage.
- the fast SR formulations of this invention exhibit plasma concentration curves having initial (e.g., from 2 hours after administration to 4 hours after administration) slopes of about 3.7 to about 11.4 ng/(mL hr) for dextroamphetamines and about 1.4 to about 3 ng/(mL hr) for levoamphetamines, preferably, about 4 to about 8 ng/(mL hr) and about 1.5 to about 2.2 ng/(mL hr), respectively.
- the precise slope for a given individual will vary according to usual factors, including whether the patient has eaten or not. For other doses, e.g., those mentioned above, the slopes vary directly (linearly) proportionally to dose.
- WO 00/23055 (whose entire disclosure is incorporated by reference herein), e.g., that for ADDERALL XR®, achieve a two-fold release of active amphetamine salts, one an immediate release dosage form and the other a delayed release dosage form.
- the lag time between the immediate release (release upon administration) and delayed release forms is 2-6 hours, preferably about 3 to about 5 hours, more preferably about 3 to about 4 hours, and typically about four hours.
- the fast sustained release formulations of this invention are used to provide a mean plasma concentration profile substantially the same as that of Example 5 (combination of Examples 1 and 2) of WO 00/23055, despite the latter's disclosure that conventional sustained release formulation technology was not suitable for amphetamines.
- Example 5 combination of Examples 1 and 2 of WO 00/23055
- conventional sustained release formulation technology was not suitable for amphetamines.
- the SR formulations of this invention will be effective to treat, e.g., ADHD, in the same manner as ADDERALL® XR. For example, they will be effective to treat ADHD in the unexpectedly good manner established in the data reported in Example 10. They will also be effective to treat ADHD with low incidence of side effects, including substance abuse, addiction, tolerance, tachyphylaxis, etc.
- Preferred salts are those in the commercial product ADDERALL XR®, i.e., dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.
- ADDERALL XR® i.e., dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.
- the invention is not limited to these specific amphetamine salts.
- Other amphetamines and amphetamine salts and mixtures thereof can be used in a sustained-release delivery system to achieve the plasma concentration profiles of the invention.
- amphetamine base, chemical and chiral derivatives thereof and other amphetamine salts can be used.
- Preferred in vivo plasma concentration profiles of the amphetamine salts can be accomplished by providing a solid dosage form of the amphetamine salts which is capable of providing a sustained release of the one or more amphetamine salts over a time period of, for example, from 8-12 hours, or longer, preferably, 10-12 hours.
- the amphetamine salts can be provided in a core which is coated with a coating which allows the release of the amphetamine salts there through over time, such as a pharmaceutically acceptable water-insoluble film former alone or with a dissolution regulating agent.
- a biphasic release profile can be achieved.
- Other methods for providing sustained-release of a drug including those further discussed below, are known and can be used to provide a sustained-release delivery which results in the above-discussed in vivo plasma concentration profile.
- Suitable sustained-release systems include SR coatings, e.g., on beads, SR matrices (i.e., no coatings needed), SR osmotic systems, etc. whereby amphetamine salts achieve a first order, biphasic, sigmoidal etc. release profile to achieve the plasma profile equivalent of pulsatile release systems of the same drugs as discussed above. Matching to the desired target plasma concentration profile using SR is conventional.
- Sustained-release beads can be prepared by coating conventional drug-containing cores with a water-insoluble polymer, or a combination of water-insoluble polymers, or a combination of water-insoluble and water-soluble polymers. This is usually not a combination of layers, but a combination of polymers in a single coating. The resultant beads (or tiny tablets) can then be placed in a capsule. Other than beads in a capsule shell, tablets in a capsule shell (e.g., one immediate-release tablet and one delayed, sustained release tablet in a capsule shell, to provide an overall sustained release) also can be used to attain the desired plasma profile.
- a multiple dosage form (e.g., as discussed below) of the present invention can deliver rapid and complete dosages of pharmaceutically active amphetamine salts to achieve the desired plasma profile of the drug in a recipient over the course of about 8-12 hours with a single oral administration.
- the levels of drug in blood plasma of the pharmaceutically active amphetamine salts will reach a peak fairly rapidly, for example, over the course of about 8 hours or less as desired, which then slowly decreases over the course of, for example, the next 12 or more hours.
- the desired plasma concentration profile can thus be achieved using a fast sustained-release once daily dosage of the amphetamine salts.
- Examples of useful bead constructions for sustained-release include the following:
- SR matrix beads can also be used, i.e., not having any needed layers to achieve sustained release.
- the components used in such matrices are chosen from conventional SR polymers.
- immediate release formulations which provide one way to achieve a desired initial fast release.
- immediate release formulations are fully conventional. See e.g., WO 00/23055.
- Suitable materials which can be used in the SR formulations of this invention are well known and include but are not limited to polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, fatty acids and their esters, alkyl alcohols, waxes, zein (prolamine from corn), and aqueous polymeric dispersions such as Eudragit RS and RL30D, Eudragit NE30D, Aquacoat, Surelease, Kollicoat SR30D, and cellulose acetate latex.
- Methods of manufacturing cores include:
- Extrusion-Spheronization the drug(s) and other additives are granulated with the addition of a binder solution. The wet mass is passed through an extruder equipped with a certain size screen. The extrudates are spheronized in a marumerizer. The resulting pellets are dried and sieved for further applications.
- High-Shear Granulation Drug(s) and other additives are dry-mixed and then the mixture is wetted by addition of a binder solution in a high shear-granulator/mixer. The granules are kneaded after wetting by the combined action of mixing and milling. The resulting granules or pellets are dried and sieved for further applications.
- Solution or Suspension Layering A drug(s) solution or dispersion with or without a binder is sprayed onto starting seeds with a certain particle size in a fluidized bed processor or other suitable equipment. The drug thus is coated on the surface of the starting seeds. The drug-loaded pellets are dried for further applications.
- the core particles preferably, have a diameter in the range of about 500-1500 microns (micrometers); more preferably 100-800 microns. These particles can then be coated in a fluidized bed apparatus with an alternating sequence of selected coating layers.
- compositions preferably in the bead forms described above, can be incorporated into hard gelatin capsules, either with additional excipients, or alone.
- Typical excipients to be added to a capsule formulation include, but are not limited to: fillers such as microcrystalline cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler.
- there can be flow aids such as fumed silicon dioxide, silica gel, magnesium stearate, calcium stearate or any other material imparting flow to powders.
- a lubricant can further be added if necessary by using, for example, polyethylene glycol, leucine, glyceryl behenate, magnesium stearate or calcium stearate.
- the composition may also be incorporated into a tablet, in particular by incorporation into a tablet matrix, which rapidly disperses the particles after ingestion.
- a filler/binder In order to incorporate these particles into such a tablet, a filler/binder must be added to a tablet that can accept the particles, but will not allow their destruction during the tableting process.
- Materials that are suitable for this purpose include, but are not limited to, microcrystalline cellulose (AVICEL.RTM.), soy polysaccharide (EMCOSOY.RTM.), pre-gelatinized starches (STARCH.RTM. 1500, NATIONAL.RTM. 1551), and polyethylene glycols (CARBOWAX.RTM.).
- the materials are preferably present in the range of 5-75% (w/w), with a more preferred range of 25-50% (w/w).
- disintegrants are optionally added in order to disperse the beads once the tablet is ingested.
- Suitable disintegrants include, but are not limited to: cross-linked sodium carboxymethyl cellulose (AC-DI-SOL.RTM.), sodium starch glycolate (EXPLOTAB.RTM., PRIMOJEL.RTM.), and cross-linked polyvinylpolypyrrolidone (Plasone-XL). These materials are preferably present in the rate of 3-15% (w/w), with a more preferred range of 5-10% (w/w).
- Lubricants are also optionally added to assure proper tableting, and these can include, but are not limited to: magnesium stearate, calcium stearate, stearic acid, polyethylene glycol, leucine, glyceryl behanate, and hydrogenated vegetable oil. These lubricants are preferably present in amounts from 0.1-10% (w/w), with a more preferred range of 0.3-3.0% (w/w).
- Tablets are formed, for example, as follows.
- the particles are introduced into a blender along with AVICEL.RTM., disintegrants and lubricant, mixed for a set number of minutes to provide a homogeneous blend which is then put in the hopper of a tablet press with which tablets are compressed.
- the compression force used is adequate to form a tablet; however, not enough to fracture the beads or coatings.
- enteric materials e.g., cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and the EUDRAGIT.RTM. acrylic polymers
- enteric materials which are soluble at higher pH values, are frequently used for colon-specific delivery systems and are entirely conventionally employable in the SR systems of this invention.
- the enteric polymers used in this invention can also be modified conventionally by mixing with other known coating products that are not pH sensitive.
- coating products include the neutral methacrylic acid esters with a small portion of trimethylammonioethyl methacrylate chloride, sold currently under the trade names EUDRAGIT.RTM. and EUDRAGIT.RTM. RL; a neutral ester dispersion without any functional groups, sold under the trade names EUDRAGIT.RTM. NE30D and EUDRAGIT.RTM. NE30; and other pH independent coating products.
- a conventional protective coating layer may also be applied immediately outside the core, either a drug-containing matrix core or a drug-layered core, by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions.
- Suitable materials for the protective layer include cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, ethyl cellulose aqueous dispersions (AQUACOAT.RTM., SURELEASE.RTM.), EUDRAGIT.RTM. RL 30D, OPADRY.RTM. and the like.
- the suggested coating levels are from 1 to 6%, preferably 2-4% (w/w).
- An overcoating layer can further optionally be applied to the composition of the present invention.
- OPADRY.RTM., OPADRY II.RTM. (Colorcon) and corresponding color and colorless grades from Colorcon can be used to protect the pellets from being tacky and provide colors to the product.
- the suggested levels of protective or color coating are from 1 to 6%, preferably 2-3% (w/w).
- ingredients can be incorporated into the overcoating formula, for example to provide a quicker (immediate) release, such as plasticizers: acetyltriethyl citrate, triethyl citrate, acetyltributyl citrate, dibutylsebacate, triacetin, polyethylene glycols, propylene glycol and the others; lubricants: talc, colloidal silica dioxide, magnesium stearate, calcium stearate, titanium dioxide, magnesium silicate, and the like.
- Optional modifying components of a protective layer which can be used over the enteric or other coatings include a water penetration barrier layer (semi-permeable polymer) which can be successively coated after the enteric or other coating to reduce the water penetration rate through the enteric coating layer and thus increase the lag time of the drug release.
- a water penetration barrier layer si-permeable polymer
- Sustained-release coatings commonly known to one skilled in the art can be used for this purpose by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions.
- the following materials can be used, but not limited to: cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, fatty acids and their esters, waxes, zein, and aqueous polymer dispersions such as EUDRAGIT.RTM. RS and RL 30D, EUDRAGIT.RTM. NE 30D, AQUACOAT.RTM., SURELEASE.RTM., cellulose acetate latex.
- hydrophilic polymers such as hydroxyethyl cellulose, hydroxypropyl cellulose (KLUCEL.RTM., Hercules Corp.), hydroxypropyl methylcellulose (METHOCEL.RTM., Dow Chemical Corp.), polyvinylpyrrolidone can also be used.
- This invention also relates to use of the SR formulations to treat indications other than ADHD at dosages and in regimens analogous to those described herein.
- these include but are not limited to Alzheimer's disease and other memory disorders, fibromyalgia, chronic fatigue, depression, obsessive compulsive disorder, alone or in combination with a SSRI; oppositional defiant disorder (ODD), with or without ADHD and with or without guanfacine or welbutrin; anxiety, with or without ADHD and alone or in combination with an anxiolytic or SSRI; resistant depression; stroke rehabilitation; Parkinson's disease; mood disorder; schizophrenia; Huntington's disorder; dementia, e.g. AIDS dementia and frontal lobe dementia; movement disfunction; apathy; fatigue; Pick's disease; sleep disorders, e.g., narcolepsy, cataplexy, sleep paralysis and hypnagogic hallucinations; etc.
- the invention also relates to combinations of the SR formulations of this invention with other therapeutic agents, including all those useful for a given indication.
- the involved drugs can be formulated in the same dosage form as the SR dose of this invention or can be formulated separately, e.g., as conventionally used alone, in which case, the drugs can be administered sequentially in any order or simultaneously.
- dosages can be in the same ranges as for each drug used separately or, where synergistic effects occur, one or more of the combined-drugs can be used in lower dosages.
- Combinations encompass any where the drugs are made bioavailable in a patient at the same time, including combinations coming into being in a patient.
- These other therapeutic agents include e.g., for Alzheimer's: Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen, Clioquinol, Ibuprofen, and Ginko Bilboa; for ADHD: methylphenidate (e.g., Ritalin), Dexedrine, Adderall, Cylert, clonidine, guanfacine, etc; for depression: Prozac, Zoloft, Paxil, Reboxetine, Wellbutrin, Olanzapine, Fluoxetine, Elavil, Totranil, Pamelor, Nardil, Parnate, Desyrel, and Effexor; for mood disorder: Thorazine, Haldol, Navane, Mellaril, Clozaril, Risperdal, Zyprexa, Clozapine, Risperidone, and Olanzapine; for fatigue: benzodiazapines, Anaprox
- Ethyl cellulose (15.46 gram) was dissolved in 515 gram of ethyl acetate.
- MASL beads Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and spray rate of 10 grams/min. The line was rinsed with ethyl acetate and the pellets were dried for approximately twenty minutes and recovered to give a product of 97% by weight MASL beads and 3% by weight ethyl cellulose coating.
- Ethyl cellulose (37.78 grams) and hydroxypropyl cellulose (8.70 grams) were dissolved in a mixture of methylene chloride and methanol (4:1).
- Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and spray rate 10 grams/min. The line was rinsed with methanol and the pellets were dried for approximately twenty minutes and recovered to give a product of 92% by weight MASL beads and 8% by weight ethyl cellulose/hydroxypropyl cellulose coating.
- Triethyl citrate was mixed into Eudragit RS30D for 30 min.
- the plasticized Eudragit RS30D was diluted with water and filtered through a 60-mesh screen.
- Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C. inlet temperature, spray pressure 1 bar, and spray rate 6 grams/min. The line was rinsed with ethyl acetate and the pellets were dried for approximately twenty minutes and recovered to give a product of 92% by weight MASL beads and 8% by weight ethyl cellulose coating.
- Eudragit L100 and ethyl cellulose were dissolved in the mixture of acetone and methanol. Subsequently, triethyl citrate was added to the polymer solution.
- Into the Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and spray rate 10 grams/min. The line was rinsed with methanol and the pellets were dried for approximately twenty minutes and recovered to give a product of 90% by weight MASL beads and 10% by weight ethyl cellulose/hydroxypropyl cellulose coating.
- All the amphetamine salts, microcrystalline cellulose, and poly(ethylene oxide) were sieved through a 60 mesh screen and loaded into a V-shaped blender with an intensifier bar.
- the powder mixture was blended for 15 min. with the intensifier bar on for 3 min. at the middle of the blending process.
- the powder blend was unloaded and screened through a 60 mesh sieve.
- the screened powder blend was lubricated with magnesium stearate in the V-shaped blender for 3 min.
- the lubricated powder blend was compacted in a roller compactor to form granules.
- All the amphetamine salts and microcrystalline cellulose were sieved through a 60 mesh screen and loaded into a V-shaped blender with an intensifier bar.
- the powder mixture was blended for 15 min. with the intensifier bar on for 3 min. at the middle of the blending process.
- the powder blend was unloaded and screened through a 60 mesh sieve.
- the screened powder blend was lubricated with magnesium stearate in the V-shaped blender for 3 min.
- the lubricated powder blend was compressed into tablets using ⁇ fraction (3/32) ⁇ ′′ tooling.
- a 2-component extended release formulation of Adderall® (mixed salts of d- and l-amphetamine) designed to produce pulse-release of medication, yields a therapeutic effect for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) that lasts throughout the day with one morning dose.
- This Adderall XRTM capsule formulation is composed of 2 types of MicrotrolTM beads of mixed salts of amphetamine in a 50:50 ratio within one capsule.
- the immediate-release beads are designed to release drug content in a time course similar to Adderall® tablets.
- the delayed-release beads are designed to release drug content approximately 4 hours after oral administration of the capsule.
- Adderall XRTM is a safe and effective medication for the community practice treatment of children with ADHD, and, although patients may be showing significant benefit on other stimulant treatment regimens, additional significant benefit may be attained by switching patients to this once-daily-dosed product.
- Adderall XR TM Current Total Daily Dose Multiplication Starting Dose Treatment (mg) Factor (mg) Adderall ® 30 ⁇ 1 30 single or 20 ⁇ 1 20 divided dose 10 ⁇ 1 10 Concerta TM 54 ⁇ 0.55 30 36 ⁇ 0.55 20 18 ⁇ 0.55 10 Methylphenidate Current total daily ⁇ 0.50, then 10, 20, (immediate and dose of rounded to or 30 sustained release, methylphenidate next lowest other than 10-mg increment Concerta TM) of Adderall XR TM Note: Patients who required a 40-mg starting dose of Adderall XR TM received two 20-mg capsules QD.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
Description
- Described herein are compositions for providing an orally administrable sustained release (SR) form of one or more amphetamines and/or amphetamine salts. Also described are methods for administering the sustained release form of one or more amphetamine salts to a patient in need thereof. Preferably, the methods are carried out for treatment of patients having ADHD (attention deficit hyperactivity disorder), but other disease states can also be treated. The sustained-release forms of one or more amphetamines and/or amphetamine salts according to the invention are preferably formulated to provide an in vivo plasma concentration profile (i.e., measured by total concentration of the amphetamines and/or amphetamine salts (often with separate tracking of d- and l-isomers) in the patients' blood plasma) which is substantially equivalent to the in vivo plasma concentration profile achieved by pulsatile release formulations of the same amphetamines and/or amphetamine salts when administered to a patient, e.g., those achieved by ADDERALL XR®, Shire US Inc., whose FDA package insert and labeling are entirely incorporated by reference herein. Further preferably, this sustained release profile (the plasma concentration profile being distinguished from the release profile) typically exhibits first order or biphasic or sigmoidal characteristics.
- Particularly preferably, the SR formulations according to the invention exhibit a single dose in vivo plasma concentration profile substantially the same as that shown in
FIG. 1 . The latter shows the substantially smooth mean (over about 20 patients) plasma concentration curves achieved for both the dextroamphetamine and levoamphetamine salts in ADDERALL XR®. (The overall mean plasma concentration curve for total amphetamine level is simply the sum of the two curves shown inFIG. 1 ). Because the formulations of this invention achieve substantially the same mean plasma concentration curves, they can be termed fast sustained release formulations, with regard to the initial rising slopes involved. - By substantially the same “profile” herein is meant that two curves have substantially the same AUC (area under the curve) and Cmax, e.g., these parameters for each curve are ±20% of each other, or even closer, e.g., ±10%, ±5%, ±2%, etc., which parameters are entirely conventionally defined and determined. See, e.g., Fundamentals of Clinical Pharmacokinetics, J. G. Wagner, Drug Intelligence Publications, Inc., Hamilton, Ill., 1975; Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, FDA, CDER, October 2000. For
FIG. 1 , AUC (time zero to infinity) is 556.6 ng hr/mL and Cmax is 28.0 ng/mL for d-amphetamine and 205.1 ng hr/mL and 8.7 ng/mL, respectively, for l-amphetamine. Of course, plasma curves achieved by this invention can follow even more closely the course of a target curve such as that shown inFIG. 1 , e.g., substantially (e.g, ±20%) matching initial rising slope, post-peak curve shapes, Tmax values, (7.1 hr for d-amphetamine and 7.4 hr for l-amphetamine forFIG. 1 ), etc. WhereasFIG. 1 shows data for 20 mg tablets (i.e., two 10 mg pulsatile doses), the plasma curves (and e.g., AUC and Cmax) corresponding to other daily doses such as 10, 30, 40, 50, 60, 70, 80, 90 mg will be essentially linearly proportional to those shown inFIG. 1 , corresponding to the involved dosage. - In another independent embodiment, the fast SR formulations of this invention, for the ADDERALL XR® 20 mg dose of
FIG. 1 , exhibit plasma concentration curves having initial (e.g., from 2 hours after administration to 4 hours after administration) slopes of about 3.7 to about 11.4 ng/(mL hr) for dextroamphetamines and about 1.4 to about 3 ng/(mL hr) for levoamphetamines, preferably, about 4 to about 8 ng/(mL hr) and about 1.5 to about 2.2 ng/(mL hr), respectively. The precise slope for a given individual will vary according to usual factors, including whether the patient has eaten or not. For other doses, e.g., those mentioned above, the slopes vary directly (linearly) proportionally to dose. - The formulations of WO 00/23055 (whose entire disclosure is incorporated by reference herein), e.g., that for ADDERALL XR®, achieve a two-fold release of active amphetamine salts, one an immediate release dosage form and the other a delayed release dosage form. Typically, the lag time between the immediate release (release upon administration) and delayed release forms is 2-6 hours, preferably about 3 to about 5 hours, more preferably about 3 to about 4 hours, and typically about four hours. In one embodiment, the fast sustained release formulations of this invention are used to provide a mean plasma concentration profile substantially the same as that of Example 5 (combination of Examples 1 and 2) of WO 00/23055, despite the latter's disclosure that conventional sustained release formulation technology was not suitable for amphetamines. (Note that the plasma profile of Example 5 shown in FIG. 7 of WO 00/23055 is not a mean profile, as is that of
FIG. 1 of this application, but rather is one from a single individual.) - The SR formulations of this invention will be effective to treat, e.g., ADHD, in the same manner as ADDERALL® XR. For example, they will be effective to treat ADHD in the unexpectedly good manner established in the data reported in Example 10. They will also be effective to treat ADHD with low incidence of side effects, including substance abuse, addiction, tolerance, tachyphylaxis, etc.
- Preferred salts are those in the commercial product ADDERALL XR®, i.e., dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate. However, the invention is not limited to these specific amphetamine salts. Other amphetamines and amphetamine salts and mixtures thereof can be used in a sustained-release delivery system to achieve the plasma concentration profiles of the invention. For example, amphetamine base, chemical and chiral derivatives thereof and other amphetamine salts can be used.
- Preferred in vivo plasma concentration profiles of the amphetamine salts can be accomplished by providing a solid dosage form of the amphetamine salts which is capable of providing a sustained release of the one or more amphetamine salts over a time period of, for example, from 8-12 hours, or longer, preferably, 10-12 hours. For example, the amphetamine salts can be provided in a core which is coated with a coating which allows the release of the amphetamine salts there through over time, such as a pharmaceutically acceptable water-insoluble film former alone or with a dissolution regulating agent. In addition, by combining the immediate-release beads with the sustained-release beads, a biphasic release profile can be achieved. Other methods for providing sustained-release of a drug, including those further discussed below, are known and can be used to provide a sustained-release delivery which results in the above-discussed in vivo plasma concentration profile.
- Suitable sustained-release systems, include SR coatings, e.g., on beads, SR matrices (i.e., no coatings needed), SR osmotic systems, etc. whereby amphetamine salts achieve a first order, biphasic, sigmoidal etc. release profile to achieve the plasma profile equivalent of pulsatile release systems of the same drugs as discussed above. Matching to the desired target plasma concentration profile using SR is conventional.
- Sustained-release beads can be prepared by coating conventional drug-containing cores with a water-insoluble polymer, or a combination of water-insoluble polymers, or a combination of water-insoluble and water-soluble polymers. This is usually not a combination of layers, but a combination of polymers in a single coating. The resultant beads (or tiny tablets) can then be placed in a capsule. Other than beads in a capsule shell, tablets in a capsule shell (e.g., one immediate-release tablet and one delayed, sustained release tablet in a capsule shell, to provide an overall sustained release) also can be used to attain the desired plasma profile.
- Various polymeric materials can be used to achieve the type of pattern of release needed to result in the desired plasma concentration profile, for example, so as to increase the fast rate of delivery over the first 4 to 8 hours of delivery. For example, a multiple dosage form (e.g., as discussed below) of the present invention can deliver rapid and complete dosages of pharmaceutically active amphetamine salts to achieve the desired plasma profile of the drug in a recipient over the course of about 8-12 hours with a single oral administration. In so doing, the levels of drug in blood plasma of the pharmaceutically active amphetamine salts will reach a peak fairly rapidly, for example, over the course of about 8 hours or less as desired, which then slowly decreases over the course of, for example, the next 12 or more hours. The desired plasma concentration profile can thus be achieved using a fast sustained-release once daily dosage of the amphetamine salts.
- Examples of useful bead constructions for sustained-release include the following:
-
- Sugar core, coated with amphetamine, coated with polymer,
- Sugar core, coated with amphetamine, coated with mix of amphetamine and polymer, coated with polymer,
- Sugar core, coated with amphetamine, coated with relatively high concentration mix of amphetamine and polymer, coated with weaker concentration mix of amphetamine and polymer, coated with polymer,
- Bead containing amphetamine, coated with polymer,
- Bead containing amphetamine, coated with mix of amphetamine and polymer, coated with polymer,
- Bead containing amphetamine, coated with relatively high concentration mix of amphetamine and polymer, coated with weaker concentration mix of amphetamine and polymer, coated with polymer, and
- Tablet or capsule containing multiple types of beads as described above having differing timing of release of amphetamine and/or different rates of release of amphetamine.
- As mentioned, SR matrix beads can also be used, i.e., not having any needed layers to achieve sustained release. The components used in such matrices are chosen from conventional SR polymers. In another construct, there can be included in the formulation, along with the layered beads or matrix beads, immediate release formulations which provide one way to achieve a desired initial fast release. Such immediate release formulations are fully conventional. See e.g., WO 00/23055.
- Details of using the foregoing constructs and others to achieve a desired plasma profile as discussed above are fully conventional and can be determined by those of skill in the art with at most a few routine parametric experiments, and conventional adjustments, e.g., involving identities of polymers and mixtures thereof, relative amounts of components, coating thicknesses, bead diameters, number of layers and compositions thereof, etc. Thus, for example, for a given construct (e.g., one of those in the examples herein), dissolution profiles can be determined and in vivo plasma profiles measured. The latter can then conventionally be compared to the target plasma profile (e.g., that of ADDERALL XR® and differences compensated by fully conventional formulation and dissolution profile adjustments such as but not limited to those mentioned.
- Suitable materials which can be used in the SR formulations of this invention are well known and include but are not limited to polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, fatty acids and their esters, alkyl alcohols, waxes, zein (prolamine from corn), and aqueous polymeric dispersions such as Eudragit RS and RL30D, Eudragit NE30D, Aquacoat, Surelease, Kollicoat SR30D, and cellulose acetate latex.
- Methods of manufacturing cores include:
- a. Extrusion-Spheronization—the drug(s) and other additives are granulated with the addition of a binder solution. The wet mass is passed through an extruder equipped with a certain size screen. The extrudates are spheronized in a marumerizer. The resulting pellets are dried and sieved for further applications.
- b. High-Shear Granulation—Drug(s) and other additives are dry-mixed and then the mixture is wetted by addition of a binder solution in a high shear-granulator/mixer. The granules are kneaded after wetting by the combined action of mixing and milling. The resulting granules or pellets are dried and sieved for further applications.
- c. Solution or Suspension Layering—A drug(s) solution or dispersion with or without a binder is sprayed onto starting seeds with a certain particle size in a fluidized bed processor or other suitable equipment. The drug thus is coated on the surface of the starting seeds. The drug-loaded pellets are dried for further applications.
- For purposes of the present invention, the core particles, preferably, have a diameter in the range of about 500-1500 microns (micrometers); more preferably 100-800 microns. These particles can then be coated in a fluidized bed apparatus with an alternating sequence of selected coating layers.
- The composition, preferably in the bead forms described above, can be incorporated into hard gelatin capsules, either with additional excipients, or alone. Typical excipients to be added to a capsule formulation include, but are not limited to: fillers such as microcrystalline cellulose, soy polysaccharides, calcium phosphate dihydrate, calcium sulfate, lactose, sucrose, sorbitol, or any other inert filler. In addition, there can be flow aids such as fumed silicon dioxide, silica gel, magnesium stearate, calcium stearate or any other material imparting flow to powders. A lubricant can further be added if necessary by using, for example, polyethylene glycol, leucine, glyceryl behenate, magnesium stearate or calcium stearate.
- The composition may also be incorporated into a tablet, in particular by incorporation into a tablet matrix, which rapidly disperses the particles after ingestion. In order to incorporate these particles into such a tablet, a filler/binder must be added to a tablet that can accept the particles, but will not allow their destruction during the tableting process. Materials that are suitable for this purpose include, but are not limited to, microcrystalline cellulose (AVICEL.RTM.), soy polysaccharide (EMCOSOY.RTM.), pre-gelatinized starches (STARCH.RTM. 1500, NATIONAL.RTM. 1551), and polyethylene glycols (CARBOWAX.RTM.). The materials are preferably present in the range of 5-75% (w/w), with a more preferred range of 25-50% (w/w).
- In addition, disintegrants are optionally added in order to disperse the beads once the tablet is ingested. Suitable disintegrants include, but are not limited to: cross-linked sodium carboxymethyl cellulose (AC-DI-SOL.RTM.), sodium starch glycolate (EXPLOTAB.RTM., PRIMOJEL.RTM.), and cross-linked polyvinylpolypyrrolidone (Plasone-XL). These materials are preferably present in the rate of 3-15% (w/w), with a more preferred range of 5-10% (w/w).
- Lubricants are also optionally added to assure proper tableting, and these can include, but are not limited to: magnesium stearate, calcium stearate, stearic acid, polyethylene glycol, leucine, glyceryl behanate, and hydrogenated vegetable oil. These lubricants are preferably present in amounts from 0.1-10% (w/w), with a more preferred range of 0.3-3.0% (w/w).
- Tablets are formed, for example, as follows. The particles are introduced into a blender along with AVICEL.RTM., disintegrants and lubricant, mixed for a set number of minutes to provide a homogeneous blend which is then put in the hopper of a tablet press with which tablets are compressed. The compression force used is adequate to form a tablet; however, not enough to fracture the beads or coatings.
- Various enteric materials, e.g., cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and the EUDRAGIT.RTM. acrylic polymers, can be used as gastroresistant, enterosoluble coatings for drug release in the intestine when desired. The enteric materials, which are soluble at higher pH values, are frequently used for colon-specific delivery systems and are entirely conventionally employable in the SR systems of this invention. The enteric polymers used in this invention can also be modified conventionally by mixing with other known coating products that are not pH sensitive. Examples of such coating products include the neutral methacrylic acid esters with a small portion of trimethylammonioethyl methacrylate chloride, sold currently under the trade names EUDRAGIT.RTM. and EUDRAGIT.RTM. RL; a neutral ester dispersion without any functional groups, sold under the trade names EUDRAGIT.RTM. NE30D and EUDRAGIT.RTM. NE30; and other pH independent coating products.
- A conventional protective coating layer may also be applied immediately outside the core, either a drug-containing matrix core or a drug-layered core, by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions. Suitable materials for the protective layer include cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, ethyl cellulose aqueous dispersions (AQUACOAT.RTM., SURELEASE.RTM.), EUDRAGIT.RTM. RL 30D, OPADRY.RTM. and the like. The suggested coating levels are from 1 to 6%, preferably 2-4% (w/w).
- An overcoating layer can further optionally be applied to the composition of the present invention. OPADRY.RTM., OPADRY II.RTM. (Colorcon) and corresponding color and colorless grades from Colorcon can be used to protect the pellets from being tacky and provide colors to the product. The suggested levels of protective or color coating are from 1 to 6%, preferably 2-3% (w/w).
- Many ingredients can be incorporated into the overcoating formula, for example to provide a quicker (immediate) release, such as plasticizers: acetyltriethyl citrate, triethyl citrate, acetyltributyl citrate, dibutylsebacate, triacetin, polyethylene glycols, propylene glycol and the others; lubricants: talc, colloidal silica dioxide, magnesium stearate, calcium stearate, titanium dioxide, magnesium silicate, and the like.
- Optional modifying components of a protective layer which can be used over the enteric or other coatings include a water penetration barrier layer (semi-permeable polymer) which can be successively coated after the enteric or other coating to reduce the water penetration rate through the enteric coating layer and thus increase the lag time of the drug release. Sustained-release coatings commonly known to one skilled in the art can be used for this purpose by conventional coating techniques such as pan coating or fluid bed coating using solutions of polymers in water or suitable organic solvents or by using aqueous polymer dispersions. For example, the following materials can be used, but not limited to: cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, fatty acids and their esters, waxes, zein, and aqueous polymer dispersions such as EUDRAGIT.RTM. RS and RL 30D, EUDRAGIT.RTM. NE 30D, AQUACOAT.RTM., SURELEASE.RTM., cellulose acetate latex. The combination of the above polymers and hydrophilic polymers such as hydroxyethyl cellulose, hydroxypropyl cellulose (KLUCEL.RTM., Hercules Corp.), hydroxypropyl methylcellulose (METHOCEL.RTM., Dow Chemical Corp.), polyvinylpyrrolidone can also be used.
- Principles of sustained release formulation technology applicable to this invention, including the exemplary modes mentioned herein, are disclosed, e.g., in R. K. Chang and J. R. Robinson, chapter 4: “Sustained Drug Release from Tablets and Particles Through Coating,” in Pharmaceutical Dosage Forms: Tablets,
volume 3, edited by H. A. Lieberman, L. Lachman, and J. B. Schwartz, Marcel Dekker, Inc., 1991; R. J. Campbell and G. L. Sackett, chapter 3: “Film coating,” in Pharmaceutical Unit Operations: Coating, edited by K. E. Avis, A. J. Shukla, and R. K. Chang, Interpharm Press, Inc., 1999, whose disclosures are entirely incorporated by reference herein. - This invention also relates to use of the SR formulations to treat indications other than ADHD at dosages and in regimens analogous to those described herein. These include but are not limited to Alzheimer's disease and other memory disorders, fibromyalgia, chronic fatigue, depression, obsessive compulsive disorder, alone or in combination with a SSRI; oppositional defiant disorder (ODD), with or without ADHD and with or without guanfacine or welbutrin; anxiety, with or without ADHD and alone or in combination with an anxiolytic or SSRI; resistant depression; stroke rehabilitation; Parkinson's disease; mood disorder; schizophrenia; Huntington's disorder; dementia, e.g. AIDS dementia and frontal lobe dementia; movement disfunction; apathy; fatigue; Pick's disease; sleep disorders, e.g., narcolepsy, cataplexy, sleep paralysis and hypnagogic hallucinations; etc.
- The invention also relates to combinations of the SR formulations of this invention with other therapeutic agents, including all those useful for a given indication. The involved drugs can be formulated in the same dosage form as the SR dose of this invention or can be formulated separately, e.g., as conventionally used alone, in which case, the drugs can be administered sequentially in any order or simultaneously. Typically, dosages can be in the same ranges as for each drug used separately or, where synergistic effects occur, one or more of the combined-drugs can be used in lower dosages. Combinations encompass any where the drugs are made bioavailable in a patient at the same time, including combinations coming into being in a patient.
- These other therapeutic agents include e.g., for Alzheimer's: Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen, Clioquinol, Ibuprofen, and Ginko Bilboa; for ADHD: methylphenidate (e.g., Ritalin), Dexedrine, Adderall, Cylert, clonidine, guanfacine, etc; for depression: Prozac, Zoloft, Paxil, Reboxetine, Wellbutrin, Olanzapine, Fluoxetine, Elavil, Totranil, Pamelor, Nardil, Parnate, Desyrel, and Effexor; for mood disorder: Thorazine, Haldol, Navane, Mellaril, Clozaril, Risperdal, Zyprexa, Clozapine, Risperidone, and Olanzapine; for fatigue: benzodiazapines, Anaprox, Naprosen, Prozac, Zoloft, Paxil, Effexor, and Desyrel; for fibromyalgia: Dilantin, Carbatrol, Epitol, Tegretol, Depacon, Depakote, Norpramin, Aventyl, Pamelor, Elavil, Enovil, Adapin, Sinequan, Zonalon, and non-steroidal inflammatory drugs; for oppositional defiant disorder (ODD): clonidine, Risperidone, and Zyprexa; for apathy: Amisulpride, Olanzapine, Visperidone, Quetiapine, Clozapine, and Zotepine; for Parkinson's disease: Levodopa, Parlodel, Permax, and MIRAPEX; for schizophrenia: Clozapine, Zyprexa, Seroquel, and Risperdal; for Huntington's disorder: haloperidal and clonzepam; for dementia: thioridazine, haloperidal, Risperidone, Cognex, Aricept, and Exelon; for narcolepsy: Provigil, Dexedrine, Modafinil and Ritalin; for cataplexy: Xyrem; for hallucinations: Clozapine, Risperidone, Zyprexa, and Seroquel; for sleep paralysis: Perocet, Vicodin, and Lorcet; for obsessive compulsive disorder: Anafranil, Prozac, Zoloft, Paxil, Luvox; and for anxiety: Elavil, Asendin, Wellbutrin, Tegretol, Anafranil, Norpramine, Adapin, Sinequan, Tofranil, Epitol, Janimire, Pamelor, Ventyl, Aventyl, Surmontil etc; selective serotonin reuptake inhibitors (SSRIs) including Prozac, Luvox, Serzone, Paxil, Zoloft, Effexor, etc., benzodiazepines, including Xanax, Librium, Klonopin, Valium, Zetran, Valrelease, Dalmane, Ativan, Alzapam, Serax, Halcion, etc., monamine oxidase inhibitors including Aurorix, Manerix, Nardil, Parnate, etc.
- The entire disclosures of all applications, patents and publication, cited above, and below, are hereby incorporated by reference.
- In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
- SR Coated Beads
-
- Mixed amphetamine salts loaded beads (MASL) 500 gram
- Ethyl cellulose (Ethocel N-10, Dow Chemical) 15.46 gram
- Ethyl acetate 515 gram
- Ethyl cellulose (15.46 gram) was dissolved in 515 gram of ethyl acetate. Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and spray rate of 10 grams/min. The line was rinsed with ethyl acetate and the pellets were dried for approximately twenty minutes and recovered to give a product of 97% by weight MASL beads and 3% by weight ethyl cellulose coating.
-
Mixed amphetamine salts loaded beads 500 grams Ethyl cellulose (Ethocel N-10, Dow Chemical) 37.78 grams Hydroxypropyl cellulose (Klucel LF, Aqualon) 8.70 grams Methylene chloride 744 grams Methanol 186 grams - Ethyl cellulose (37.78 grams) and hydroxypropyl cellulose (8.70 grams) were dissolved in a mixture of methylene chloride and methanol (4:1). Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and
spray rate 10 grams/min. The line was rinsed with methanol and the pellets were dried for approximately twenty minutes and recovered to give a product of 92% by weight MASL beads and 8% by weight ethyl cellulose/hydroxypropyl cellulose coating. -
Mixed amphetamine salts loaded beads 500 gram Surelease (Ethyl cellulose-based 173.92 grams dispersion, Colorcon) Water 43.48 grams - Surelease (173.92 grams) was diluted with 43.48 grams of water. Into a Wurster column (Versa-Glatt, Glatt Air Techniques) was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 60° C. inlet temperature, spray pressure 1 bar, and spray rate 6 grams/min. The line was rinsed with water and the pellets were dried for approximately twenty minutes and recovered to give a product of 92% by weight MASL beads and 8% by weight ethyl cellulose coating.
-
Mixed amphetamine salts loaded beads 500 grams Eudragit RS30D 111.49 grams Triethyl citrate 10.03 grams Water 115.94 grams - Triethyl citrate was mixed into Eudragit RS30D for 30 min. The plasticized Eudragit RS30D was diluted with water and filtered through a 60-mesh screen. Into a Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C. inlet temperature, spray pressure 1 bar, and spray rate 6 grams/min. The line was rinsed with ethyl acetate and the pellets were dried for approximately twenty minutes and recovered to give a product of 92% by weight MASL beads and 8% by weight ethyl cellulose coating.
-
Mixed amphetamine salts loaded beads 500 grams Mixed amphetamine salts 48.5 grams Glyceryl behenate (Compritol 888, Gattefosse) 436.5 grams - Mixed amphetamine salts was dispersed in the molten glyceryl behenate. The drug-containing hot melt was sprayed onto the mixed amphetamine salts loaded beads in a Wurster column under conditions of 30° C. inlet temperature,
spray pressure 2 bar, and a spray rate of 10 grams/min. -
Mixed amphetamine salts loaded beads 500 grams Eudragit L100 25.25 grams Ethyl cellulose (Ethocel N-10, Dow Chemical) 25.25 grams Triethyl citrate 5.05 grams Acetone 833.4 grams Methanol 277.8 grams - Eudragit L100 and ethyl cellulose were dissolved in the mixture of acetone and methanol. Subsequently, triethyl citrate was added to the polymer solution. Into the Wurster column was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 40° C., spray pressure 1 bar, and
spray rate 10 grams/min. The line was rinsed with methanol and the pellets were dried for approximately twenty minutes and recovered to give a product of 90% by weight MASL beads and 10% by weight ethyl cellulose/hydroxypropyl cellulose coating. - SR Matrix Beads/Tablets
-
Amphetamine Aspartate 50 grams Amphetamine Sulfate 50 grams Dextroamphetamine saccharate 50 grams Dextroamphetamine sulfate 50 grams Microcrystalline cellulose 400 grams Poly(ethylene oxide), Polyox WSR 303 1380 grams Magnesium stearate 20 grams - All the amphetamine salts, microcrystalline cellulose, and poly(ethylene oxide) were sieved through a 60 mesh screen and loaded into a V-shaped blender with an intensifier bar. The powder mixture was blended for 15 min. with the intensifier bar on for 3 min. at the middle of the blending process. The powder blend was unloaded and screened through a 60 mesh sieve. The screened powder blend was lubricated with magnesium stearate in the V-shaped blender for 3 min. The lubricated powder blend was compacted in a roller compactor to form granules.
-
Amphetamine Aspartate 50 grams Amphetamine Sulfate 50 grams Dextroamphetamine saccharate 50 grams Dextroamphetamine sulfate 50 grams Microcrystalline cellulose 1780 grams Magnesium stearate 20 grams - All the amphetamine salts and microcrystalline cellulose were sieved through a 60 mesh screen and loaded into a V-shaped blender with an intensifier bar. The powder mixture was blended for 15 min. with the intensifier bar on for 3 min. at the middle of the blending process. The powder blend was unloaded and screened through a 60 mesh sieve. The screened powder blend was lubricated with magnesium stearate in the V-shaped blender for 3 min. The lubricated powder blend was compressed into tablets using {fraction (3/32)}″ tooling.
-
Mini-tablets 500 grams Surelase 127.7 grams water 85.1 grams - Surelease (127.7 grams) was diluted with 85.1 grams of water. Into the Wurster column (Versa-Glatt, Glatt Air Techniques) was charged 500 grams of the mini-tablets which were then coated with the coating mixture under conditions of 60 C. inlet temperature, spray pressure 1 bar, and spray rate 6 grams/min. The line was rinsed with water and the pellets were dried for approximately twenty minutes and recovered to give a product of 94% by weight MASL minitablets and 6% by weight ethyl cellulose coating.
-
Mixed amphetamine salts loaded beads 500 grams Surlease (Ethyl cellulose-based 272.7 grams dispersion, Colorcon) Water 68.2 grams - Surelease (272.7 grams) was diluted with 68.2 grams of water. Into a Wurster column (Versa-Glatt, Glatt Air Techniques) was charged 500 grams of MASL beads which were then coated with the coating mixture under conditions of 60 degree C. inlet temperature, spray pressure 1 bar, and spray rate 6 grams/min. The line was rinsed with water and the pellets were dried for approximately twenty minutes and recovered to give a product of 88% by weight MASL beads and 12% by weight ethyl cellulose coating.
- The dissolution data for 8% and 12% coating levels are summarized as follows:
1 hour 2 hours 4 hours 6 hours 8 hours 8% coating 45% 74% 93% 98% 100% 12 % coating 25% 47% 70% 81% 87% - A 2-component extended release formulation of Adderall® (mixed salts of d- and l-amphetamine) designed to produce pulse-release of medication, yields a therapeutic effect for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) that lasts throughout the day with one morning dose. This Adderall XR™ capsule formulation is composed of 2 types of Microtrol™ beads of mixed salts of amphetamine in a 50:50 ratio within one capsule. The immediate-release beads are designed to release drug content in a time course similar to Adderall® tablets. The delayed-release beads are designed to release drug content approximately 4 hours after oral administration of the capsule. An initial formulation study with
Adderall XR™ 20 mg QD demonstrated comparable bioavailability and pharmacokinetic profiles to immediate-release Adderall® 10 mg BID with a 4-hour interval and concluded thatAdderall XR™ 20 mg QD is bioequivalent toAdderall® 10 mg BID (Michaels et al. Presented, NCDEU 2001). - The efficacy and extended duration of action of Adderall XR™ in the treatment of children with ADHD has been demonstrated in 2 previous pivotal double-blind studies: one conducted in a laboratory classroom setting (McCracken et al. Submitted), and the other in a naturalistic home and school environment (Biederman et al. Pediatrics 2002. In press). This large-scale, open-label trial has been conducted primarily to evaluate the tolerability and effectiveness of Adderall XR™ in the treatment of pediatric ADHD in the community practice setting.
- Presented here are unaudited data of this prospective, open-label, 7-week study conducted at 378 sites nationwide. An 8-week extension arm was optional after completion of this initial phase (Diagram A).
- Subjects: Children aged 6 to 12 years who had a DSM-IV diagnosis of ADHD and were currently taking stable doses of immediate-release Adderall® or any methylphenidate formulation were enrolled.
- Inclusion Criteria: Good physical health with normal blood pressure, pulse, and electrocardiogram (ECG); Conners Global Index Scale—Parent (CGIS-P) rating score of <—12 for boys and <—10 for girls; known responder to psychostimulant medication. Exclusion Criteria: Uncontrolled, symptomatic comorbid psychiatric disorder; IQ<80; history of seizure disorder or Tourette's; concomitant medications, such as clonidine, guanfacine, anticonvulsants, or any medications that affect blood pressure or the heart.
Measures: - Primary Efficacy: Validated CGIS-P
- Baseline: 2 to 3 hours after morning dose of previous psychostimulant medication to assess degree of control of symptoms plus additional assessments at 8 and 12 hours after dose
- Following initiation of treatment with Adderall XR™: prior to clinic visit at
weeks - Subjects rated for severity at baseline while on previous psychostimulant medication. The CGI-S is a 7-point scale ranging from 1 (normal/not ill at all) to 7 (extremely ill).
- Subjects rated for improvement at
weeks - Primary Tolerability: Pediatric quality of life (PedsQL™)
- Validated measure assessing age-specific quality-of-life markers in healthy children and those with acute and chronic health conditions.
- Completed by parent/caregiver at baseline and end of initial phase of study (week 7).
- Secondary Tolerability: Medication Satisfaction and Preference Instruments Scales allowing evaluation of the acceptability of Adderall XR™ by both the parent/caregiver and physician (separate scales for physician and parent). Satisfaction Instrument given at baseline and
week 7. Preference Instrument given atweek 7. - Primary Safety: Physical exam at screening (including height and weight); ECG baseline and end of study; vital signs, including pulse, blood pressure, and weight at each study visit; spontaneously reported adverse events (AEs) were recorded at each visit.
- In children receiving stable doses of various stimulant medications, 8- and 12-hour post-dose CGIS-P scores reveal significant improvement in ADHD symptoms after conversion to Adderall XR™.
- After switching to Adderall XR™, significant improvement was also apparent in CGI improvement scores and pediatric quality-of-life measures.
- In this real-world clinical experience trial, satisfaction and preference survey results from both physicians and parents/caregivers (although not fully depicted here) also suggest significant benefit from treatment with Adderall XR™ as compared to previous medication therapy.
- These findings likely reflect (1) the established efficacy and longer duration of action of Adderall XR™, (2) elimination of the need for additional daily doses for patients in multiple-daily-dose groups (at baseline), and (3) the lower daily doses of stimulant medication treatment regimens and higher level of ADHD symptomatology previously identified with ADHD treatment regimens in the community practice setting.
- The incidence of adverse events occurring during treatment was low, and the majority of AEs were mild in nature; study medication was well tolerated. Adderall XR™ is a safe and effective medication for the community practice treatment of children with ADHD, and, although patients may be showing significant benefit on other stimulant treatment regimens, additional significant benefit may be attained by switching patients to this once-daily-dosed product.
TABLE 1 Medication Conversion Paradigm Adderall XR ™ Current Total Daily Dose Multiplication Starting Dose Treatment (mg) Factor (mg) Adderall ® 30 ×1 30 single or 20 ×1 20 divided dose 10 ×1 10 Concerta ™ 54 ×0.55 30 36 ×0.55 20 18 ×0.55 10 Methylphenidate Current total daily ×0.50, then 10, 20, (immediate and dose of rounded to or 30 sustained release, methylphenidate next lowest other than 10-mg increment Concerta ™) of Adderall XR ™
Note:
Patients who required a 40-mg starting dose of Adderall XR ™ received two 20-mg capsules QD.
- Of the 2968 subjects who received study medication, 2911 (98%) had at least one post-baseline CGIS-P total score available for efficacy analysis. These subjects make up the intent-to-treat (ITT) population (Table 2).
TABLE 2 Demographic and Baseline Information All Participants ITT Subjects Subject Population (N = 2968) (n = 2911) Age (y), mean ± SD 9.5 ± 1.8 9.5 ± 1.8 Gender 76% male 76% male Race White 88.0% 88.0% Black 6.7% 6.7% Hispanic 3.5% 3.4% Other 1.8% 1.9% Diagnosis Combined 2072 (70.2%) 2034 (70.2%) Inattentive 682 (23.1%) 669 (23.1%) Hyperactive 197 (6.7%) 193 (6.7%) Comorbidity Oppositional defiant 109 (3.7%) 103 (3.5%) Conduct disorder 16 (0.5%) 16 (0.5%) Anxiety 83 (2.8%) 83 (2.9%) Depression 93 (3.1%) 91 (3.1%) Obsessive-compulsive disorder 42 (1.4%) 41 (1.4%) Other 78 (2.6%) 76 (2.6%)
˜Mean CGIS-P baseline score at 2 to 3 hours after morning dose of previous medication = 5.9.
- Individual patients were treated with ADDERALL XR®, 20 mg. Subjects received either one single dose administered with food or one single dose administered following a 10-hour overnight fast through continued fast 3.5 hours post dosing. A sampling of individuals' curves is given in
FIGS. 7-12 . The mean plasma concentration profile ofFIG. 1 was obtained from averaging such individuals' curves. - The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (22)
1. A pharmaceutical composition comprising a once-a-day sustained release formulation of at least one amphetamine salt which provides a mean plasma concentration profile in human ADHD patients which is substantially the same as that provided by a formulation thereof comprising an immediate release dose and a dose delayed therefrom by about 2 to about 6 hours.
2. A pharmaceutical composition of claim 1 wherein the immediate and delayed release doses are the same.
3. The pharmaceutical composition of claim 2 , wherein the at least one amphetamine or amphetamine salt is a mixture of two or more amphetamine salts.
4. The pharmaceutical composition of claim 2 , wherein at least one amphetamine or amphetamine salt is a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.
5. A pharmaceutical composition of claim 4 , wherein said profile is substantially the same as that of FIG. 1 .
6. A pharmaceutical composition comprising a once-a-day sustained release formulation of at least one amphetamine salt which provides a mean plasma concentration profile in human ADHD patients which is substantially the same as that of FIG. 1 .
7. The composition of claim 6 , wherein at least one amphetamine or amphetamine salt is a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate.
8. The pharmaceutical composition of claim 7 , wherein the dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate salts are administered in equal amounts by weight.
9. The pharmaceutical composition of claim 6 , wherein the at least one amphetamine or amphetamine salt is provided in a core which is coated with a coating comprising a pharmaceutically acceptable water-insoluble film former or other polymer providing sustained release.
10. The pharmaceutical composition of claim 9 , wherein the coating further comprises a dissolution regulating agent.
11. A pharmaceutical composition of claim 1 comprising a sustained-release formulation of said salt(s) and a dosage form for immediate release of at least one amphetamine salt.
12. The pharmaceutical composition of claim 6 , wherein the at least one amphetamine or amphetamine salt is provided in a sustained release matrix.
13. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 1 .
14. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 5 .
15. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 6 .
16. A pharmaceutical composition comprising a once-a-day sustained release formulation of at least one amphetamine salt which provides a mean plasma concentration profile in human ADHD patients which has substantially the same initial slope as that of FIG. 1 .
17. A pharmaceutical composition comprising a once-a-day sustained release formulation of amphetamine salts which provides a mean plasma concentration profile in human ADHD patients which has an initial slope of about 3.7 to about 11.4 ng/(mL hr) for dextroamphetamines and about 1.4 to about 3 ng/(mL hr) for levoamphetamines, all at a total amphetamine dose of 20 mg, or an initial slope directly proportional thereto for a total dose other than 20 mg.
18. A pharmaceutical composition comprising a once-a-day sustained release formulation of at least one amphetamine salt which provides a mean plasma concentration profile in human ADHD patients which has an initial slope of about 4 to about 8 ng/(mL hr) for dextroamphetamines and about 1.5 to about 2.2 ng/(mL hr) for levoamphetamines.
19. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 16 .
20. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a pharmaceutical composition of claim 17 .
21. A pharmaceutical composition comprising a once-a-day sustained release formulation of at least one amphetamine salt which provides a mean plasma concentration profile in human ADHD patients which has an AUC of 556.6 mg hr/mL±20% and a Cmax of 28.0 ng/mL±20% for d-amphetamine and an AUC of 205.1 ng hr/mL±20% and a Cmax of 8.7 ng/mL±20% for l-amphetamine.
22. A method for treating attention deficit hyperactivity disorder which comprises administering to a human patient in need thereof a once-a-day sustained release formulation which provides a mean plasma concentration profile in human ADHD patients which has an AUC of 556.6 mg hr/mL±20% and a Cmax of 28.0 ng/mL±20% for d-amphetamine and an AUC of 205.1 ng hr/mL±20% and a Cmax of 8.7 ng/mL±20% for l-amphetamine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/030,174 US20050158384A1 (en) | 2002-09-24 | 2005-01-07 | Sustained release delivery of amphetamine salts |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41279902P | 2002-09-24 | 2002-09-24 | |
US10/353,073 US6913768B2 (en) | 2002-09-24 | 2003-01-29 | Sustained release delivery of amphetamine salts |
US11/030,174 US20050158384A1 (en) | 2002-09-24 | 2005-01-07 | Sustained release delivery of amphetamine salts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/353,073 Continuation US6913768B2 (en) | 2002-09-24 | 2003-01-29 | Sustained release delivery of amphetamine salts |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050158384A1 true US20050158384A1 (en) | 2005-07-21 |
Family
ID=31996998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/353,073 Expired - Lifetime US6913768B2 (en) | 2002-09-24 | 2003-01-29 | Sustained release delivery of amphetamine salts |
US11/030,174 Abandoned US20050158384A1 (en) | 2002-09-24 | 2005-01-07 | Sustained release delivery of amphetamine salts |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/353,073 Expired - Lifetime US6913768B2 (en) | 2002-09-24 | 2003-01-29 | Sustained release delivery of amphetamine salts |
Country Status (30)
Country | Link |
---|---|
US (2) | US6913768B2 (en) |
EP (1) | EP1542660B1 (en) |
JP (1) | JP2006503071A (en) |
KR (1) | KR20050084589A (en) |
CN (1) | CN1684668B (en) |
AP (1) | AP2030A (en) |
AT (1) | ATE495731T1 (en) |
AU (1) | AU2003272619B2 (en) |
BR (1) | BR0314486A (en) |
CA (1) | CA2499546C (en) |
CR (1) | CR7766A (en) |
CY (1) | CY1112335T1 (en) |
DE (1) | DE60335807D1 (en) |
DK (1) | DK1542660T3 (en) |
EA (1) | EA018082B1 (en) |
EC (1) | ECSP055702A (en) |
ES (1) | ES2360046T3 (en) |
HK (1) | HK1075828A1 (en) |
HR (1) | HRP20050356A2 (en) |
IL (1) | IL167470A (en) |
IS (1) | IS2814B (en) |
MA (1) | MA27469A1 (en) |
MX (1) | MXPA05003129A (en) |
NO (1) | NO336938B1 (en) |
NZ (1) | NZ539216A (en) |
OA (1) | OA13075A (en) |
PL (1) | PL375991A1 (en) |
SI (1) | SI1542660T1 (en) |
WO (1) | WO2004028509A1 (en) |
ZA (1) | ZA200502406B (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069871A1 (en) * | 2006-07-21 | 2008-03-20 | Vaughn Jason M | Hydrophobic abuse deterrent delivery system |
US20110008426A1 (en) * | 2008-03-05 | 2011-01-13 | Rajesh Jain | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
US20130079415A1 (en) * | 2010-02-16 | 2013-03-28 | Jagotec Ag | Compositions comprising amphetamin and lisdexamfetamine |
WO2014058742A1 (en) * | 2012-10-09 | 2014-04-17 | Sears Douglas | Therapeutic treatment |
US20140227197A1 (en) * | 2011-03-23 | 2014-08-14 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
US20150231125A1 (en) * | 2011-03-23 | 2015-08-20 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
AU2018202002B2 (en) * | 2011-03-23 | 2019-04-04 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10736866B2 (en) | 2016-07-22 | 2020-08-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10925844B2 (en) | 2019-03-01 | 2021-02-23 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11241392B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
WO2004071501A1 (en) * | 2003-02-10 | 2004-08-26 | Shire Biochem Inc. | Enantiomeric amphetamine compositions for the treatment of adhd |
DK2204168T3 (en) | 2003-04-07 | 2015-04-07 | Supernus Pharmaceuticals Inc | Tetracycline for administration once a day |
KR101159477B1 (en) * | 2003-05-29 | 2012-07-02 | 샤이어 엘엘씨 | Abuse resistant amphetamine compounds |
AP1899A (en) * | 2003-08-08 | 2008-10-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
SG157415A1 (en) | 2004-11-23 | 2009-12-29 | Adamas Pharmaceuticals Inc | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
CA2588296A1 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US9713592B2 (en) * | 2005-04-06 | 2017-07-25 | Mallinckrodt Llc | Matrix-based pulse release pharmaceutical formulation |
WO2006121560A2 (en) * | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
RU2435569C2 (en) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Compositions with modified release, containing complexes medication-ion-exchanging resin |
WO2007120648A2 (en) * | 2006-04-10 | 2007-10-25 | Shire Llc | Mono and di-substituted oxycodone compounds and compositions |
US20070253927A1 (en) * | 2006-04-13 | 2007-11-01 | Gwenaelle Jegou | Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator |
EP2007389A2 (en) * | 2006-04-14 | 2008-12-31 | Shire LLC | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
MX2008014455A (en) * | 2006-05-12 | 2008-11-27 | Shire Llc | Controlled dose drug delivery system. |
US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
KR100774613B1 (en) * | 2006-05-26 | 2007-11-12 | 한국화학연구원 | Sustained release drug delivery system composed of water insoluble polymer |
US20080207668A1 (en) * | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
US20080090771A1 (en) * | 2006-10-06 | 2008-04-17 | Shire Llc | Abuse-resistant hydrocodone compounds, compositions and methods of using the same |
JP2010522135A (en) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
CA2678806C (en) * | 2007-02-21 | 2017-05-16 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
US20080268047A1 (en) * | 2007-04-24 | 2008-10-30 | Xavier University Of Louisiana | Controlled Release Multiple Layer Coatings |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
EP2560624B1 (en) | 2010-04-23 | 2018-07-04 | KemPharm, Inc. | Therapeutic formulation for reduced drug side effects |
US8927010B2 (en) * | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) * | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
EP2768481A4 (en) | 2011-10-21 | 2015-07-08 | Subhash Desai | Compositions for reduction of side effects |
BR112015003120B1 (en) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | METHYLPHENIDATE EXTENDED RELEASE CHEW TABLET AND ITS USE |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
BR112018012870A2 (en) | 2015-12-30 | 2018-12-04 | Adamas Pharmaceuticals Inc | methods and compositions for the treatment of crisis-related disorders |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
BR112020003375A2 (en) | 2017-08-24 | 2020-08-25 | Adamas Pharma, Llc | amantadine compositions, preparations thereof, and methods of use |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
AU2020259406A1 (en) | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4049791A (en) * | 1974-06-21 | 1977-09-20 | Delco Chemical Company, Inc. | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6217904B1 (en) * | 1999-04-06 | 2001-04-17 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
US20040220277A1 (en) * | 2003-02-10 | 2004-11-04 | Couch Richard A. | Enantiomeric amphetamine compositions |
US20040219213A1 (en) * | 1998-10-21 | 2004-11-04 | Burnside Beth A. | Oral pulsed dose drug delivery system |
US20050080012A1 (en) * | 2002-02-22 | 2005-04-14 | New River Pharmaceuticals Inc. | Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
US20070264323A1 (en) * | 2006-05-12 | 2007-11-15 | Shire Llc | Controlled dose drug delivery system |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768512A (en) | 1954-08-16 | 1957-02-20 | Smith Kline & French Internat | Improvements in or relating to pharmaceutical tablets |
FR2470599A1 (en) | 1979-12-07 | 1981-06-12 | Panoz Donald | IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
WO1987000044A1 (en) | 1985-07-02 | 1987-01-15 | The Upjohn Company | Therapeutic formulations with bimodal release characteristics |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
DE3678644D1 (en) | 1985-08-16 | 1991-05-16 | Procter & Gamble | ACTIVE PARTICLES WITH A CONTINUOUS THAN FASTER RELEASE. |
JPS62103012A (en) | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | Multi-layered granule |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
DE3712095A1 (en) | 1987-04-10 | 1988-10-20 | Lentia Gmbh | BINDER-FREE GRANULES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES |
DE3827214A1 (en) | 1988-08-11 | 1990-02-15 | Roehm Gmbh | RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF |
US5275819A (en) | 1989-02-06 | 1994-01-04 | Amer Particle Technologies Inc. | Drug loaded pollen grains with an outer coating for pulsed delivery |
RU2104084C1 (en) | 1989-02-16 | 1998-02-10 | Бритиш Технолоджи Груп Лимитед | Capsule of metered ejection |
WO1991003510A1 (en) | 1989-08-28 | 1991-03-21 | Pharmaceutical Delivery Systems, Inc. | Bioerodible polymers useful for the controlled release of therapeutic agents |
JPH0674206B2 (en) | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | Controlled release formulation and process for producing |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5232705A (en) | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
IE70328B1 (en) | 1991-01-30 | 1996-11-13 | Alza Corp | Osmotic device for delayed delivery of agent |
US5226902A (en) | 1991-07-30 | 1993-07-13 | University Of Utah | Pulsatile drug delivery device using stimuli sensitive hydrogel |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
JPH07509702A (en) | 1992-08-05 | 1995-10-26 | エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド | pellet drug composition |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
JP2916978B2 (en) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | Controlled release initiation type formulation |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
FR2723536A1 (en) | 1994-08-11 | 1996-02-16 | Seth Pawan | COMPOSITION FOR SELECTIVE RELEASE OF AN ACTIVE INGREDIENT |
US5731314A (en) | 1995-01-06 | 1998-03-24 | Bencherif; Merouane | Pharamceutical compositions for prevention and treatment of tourette's syndrome |
WO1997003672A1 (en) | 1995-07-14 | 1997-02-06 | Chiroscience Limited | THERAPEUTIC USE OF d-threo-METHYLPHENIDATE |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
IL142896A0 (en) | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
-
2003
- 2003-01-29 US US10/353,073 patent/US6913768B2/en not_active Expired - Lifetime
- 2003-09-24 MX MXPA05003129A patent/MXPA05003129A/en active IP Right Grant
- 2003-09-24 OA OA1200500086A patent/OA13075A/en unknown
- 2003-09-24 ZA ZA200502406A patent/ZA200502406B/en unknown
- 2003-09-24 DE DE60335807T patent/DE60335807D1/en not_active Expired - Lifetime
- 2003-09-24 PL PL03375991A patent/PL375991A1/en not_active Application Discontinuation
- 2003-09-24 WO PCT/US2003/029757 patent/WO2004028509A1/en active Application Filing
- 2003-09-24 BR BR0314486-0A patent/BR0314486A/en not_active Application Discontinuation
- 2003-09-24 CA CA002499546A patent/CA2499546C/en not_active Expired - Lifetime
- 2003-09-24 SI SI200331985T patent/SI1542660T1/en unknown
- 2003-09-24 AP AP2005003275A patent/AP2030A/en active
- 2003-09-24 ES ES03754811T patent/ES2360046T3/en not_active Expired - Lifetime
- 2003-09-24 EA EA200500530A patent/EA018082B1/en not_active IP Right Cessation
- 2003-09-24 AT AT03754811T patent/ATE495731T1/en active
- 2003-09-24 EP EP03754811A patent/EP1542660B1/en not_active Expired - Lifetime
- 2003-09-24 JP JP2004540151A patent/JP2006503071A/en active Pending
- 2003-09-24 NZ NZ539216A patent/NZ539216A/en not_active IP Right Cessation
- 2003-09-24 DK DK03754811.2T patent/DK1542660T3/en active
- 2003-09-24 KR KR1020057005127A patent/KR20050084589A/en not_active Application Discontinuation
- 2003-09-24 CN CN038227029A patent/CN1684668B/en not_active Expired - Fee Related
- 2003-09-24 AU AU2003272619A patent/AU2003272619B2/en not_active Ceased
-
2005
- 2005-01-07 US US11/030,174 patent/US20050158384A1/en not_active Abandoned
- 2005-03-16 IL IL167470A patent/IL167470A/en active IP Right Grant
- 2005-03-18 CR CR7766A patent/CR7766A/en unknown
- 2005-03-21 MA MA28168A patent/MA27469A1/en unknown
- 2005-03-23 EC EC2005005702A patent/ECSP055702A/en unknown
- 2005-04-20 HR HR20050356A patent/HRP20050356A2/en not_active Application Discontinuation
- 2005-04-22 IS IS7818A patent/IS2814B/en unknown
- 2005-04-22 NO NO20051986A patent/NO336938B1/en not_active IP Right Cessation
- 2005-09-08 HK HK05107892.9A patent/HK1075828A1/en not_active IP Right Cessation
-
2011
- 2011-04-15 CY CY20111100379T patent/CY1112335T1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4049791A (en) * | 1974-06-21 | 1977-09-20 | Delco Chemical Company, Inc. | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US20040219213A1 (en) * | 1998-10-21 | 2004-11-04 | Burnside Beth A. | Oral pulsed dose drug delivery system |
US6217904B1 (en) * | 1999-04-06 | 2001-04-17 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
US20050080012A1 (en) * | 2002-02-22 | 2005-04-14 | New River Pharmaceuticals Inc. | Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
US20040220277A1 (en) * | 2003-02-10 | 2004-11-04 | Couch Richard A. | Enantiomeric amphetamine compositions |
US20070264323A1 (en) * | 2006-05-12 | 2007-11-15 | Shire Llc | Controlled dose drug delivery system |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069871A1 (en) * | 2006-07-21 | 2008-03-20 | Vaughn Jason M | Hydrophobic abuse deterrent delivery system |
US20110008426A1 (en) * | 2008-03-05 | 2011-01-13 | Rajesh Jain | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
US8927608B2 (en) * | 2010-02-16 | 2015-01-06 | Jagotec Ag | Compositions comprising amphetamin and lisdexamfetamine |
US20130079415A1 (en) * | 2010-02-16 | 2013-03-28 | Jagotec Ag | Compositions comprising amphetamin and lisdexamfetamine |
US10881618B2 (en) | 2011-03-23 | 2021-01-05 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US20150231125A1 (en) * | 2011-03-23 | 2015-08-20 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) * | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9289394B2 (en) | 2011-03-23 | 2016-03-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241392B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9511032B2 (en) | 2011-03-23 | 2016-12-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603808B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Method of treatment of attention deficit hyperactivity disorder |
US20140227197A1 (en) * | 2011-03-23 | 2014-08-14 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
US9889095B2 (en) | 2011-03-23 | 2018-02-13 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10179108B2 (en) | 2011-03-23 | 2019-01-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10182995B2 (en) | 2011-03-23 | 2019-01-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
AU2018202002B2 (en) * | 2011-03-23 | 2019-04-04 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10617651B2 (en) | 2011-03-23 | 2020-04-14 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11911518B2 (en) | 2011-03-23 | 2024-02-27 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
WO2014058742A1 (en) * | 2012-10-09 | 2014-04-17 | Sears Douglas | Therapeutic treatment |
US10682409B2 (en) | 2012-10-09 | 2020-06-16 | Attentive Therapeutics, Inc. | Therapeutic treatment |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11052061B2 (en) | 2016-07-22 | 2021-07-06 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11065224B2 (en) | 2016-07-22 | 2021-07-20 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10973795B2 (en) | 2016-07-22 | 2021-04-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10952986B2 (en) | 2016-07-22 | 2021-03-23 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10736866B2 (en) | 2016-07-22 | 2020-08-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US10925844B2 (en) | 2019-03-01 | 2021-02-23 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6913768B2 (en) | Sustained release delivery of amphetamine salts | |
US20180344669A1 (en) | Controlled dose drug delivery system | |
EP2023900B1 (en) | Controlled dose drug delivery system | |
US10881618B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
US9283214B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
US20150313849A1 (en) | Methods of Treatment of Attention Deficit Hyperactivity Disorder | |
US10292937B2 (en) | Methods of treatment of attention deficit hyperactivity disorder | |
US11911518B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
US10905652B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
US20240226023A1 (en) | Compositions for Treatment of Attention Deficit Hyperactivity Disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHIRE LLC, KENTUCKY Free format text: MERGER;ASSIGNOR:SHIRE LABORATORIES, INC.;REEL/FRAME:018654/0073 Effective date: 20061215 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |